arrivent.com (AVBP) Net Asset Value

AVBP (ArriVent Corp) - company brandmark

The market valuation dynamics for ArriVent BioPharma, Inc (AVBP) demonstrate a current figure of 0.37. ArriVent BioPharma, Inc develops targeted lung tumor treatments using brain-penetrating molecules to combat metastases. The business is currently incurring colossal clinical trial costs, which temporarily limits operational efficiency. The development strategy relies on global alliances to expand innovative drugs into Western markets.

ArriVent BioPharma, Inc. (AVBP) Company Net Assets: for the period 02/21/2024 - 10/28/2026

Analytical breakdowns for ArriVent BioPharma, Inc (AVBP)

- price and consensus price forecast:
Price Chart ArriVent|AVBP - Price Target Chart
- market capitalization data:
Market Valuation ArriVent BioPharma Inc|AVBP - Total Company Value
- book capitalization data:
Net Assets per Single Share ArriVent BioPharma|AVBP - Company Net Assets|Market Capitalization to Book Value Ratio arrivent.com|AVBP - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio ArriVent BioPharma, Inc|AVBP - Long-Term Debt to Capital|Short-Term Indebtedness to Equity arrivent.com|AVBP - Company Debts|Debts to Net Assets ArriVent BioPharma Inc|AVBP - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings ArriVent BioPharma
Summary company analytics:ArriVent BioPharma, Inc
Mass-produced product of ArriVent Corp

The scientific potential of ArriVent BioPharma, Inc (AVBP) in developing targeted EGFR inhibitors determines the financial stability of the business. By analyzing the level of equity based on book value, an investor sees the real value of net assets minus all liabilities. This metric measures the company's internal resources allocated to costly R&D projects. The trend of this indicator reveals critical cycle inflection points, allowing for the determination of the fair value of assets during periods of market volatility.

Competitors of ArriVent BioPharma, Inc

LTRN: Company Book Value|Company Book Value bioaffinitytech.com (BIAF)|EFTR (effector.com) - Net Asset Value